Shanghai Ambrosia Pharmaceutical, Ltd. is a privately-owned biopharmaceutical company dedicated to the discovery and development of novel therapeutics and health products for the treatment of cancer and immune diseases. The Shanghai Ambrosia was established in 2002 at the Shanghai Zhang-Jiang High Tech Park of China by a group of world-renowned scientists from the United States and China.
The focus of the company is to develop novel drug screening assays and to discover proprietary new drugs to meet important unmet medical needs in cancer and immune system diseases.
The strategy of the companyis to apply the most advanced scientific discovery and technology to identify effective compounds from traditional Chinese herb medicine and to discover novel use of known drugs.
The core technology of the Shanghai Ambrosia is our novel cell and signaling pathway-based drug screen platforms, which are built upon the primary discoveries from laboratories of our scientific founders who are world leaders in their fields.
The major products of the Shanghai Ambrosia are novel drug leads, drugs, and other health products, primarily targeting cancer and immune system diseases.
